Lucia Trastulla

Lucia Trastulla

Auto-generated profile, based on publicly available information

Lucia Trastulla

Human Technopole

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
NKNils Kappelmann
Nils Kappelmann
DCDarina Czamara
Darina Czamara
NRNicolas Rost
Nicolas Rost
SMSylvain Moser
Sylvain Moser
VSVanessa Schmoll
Vanessa Schmoll
JAJanine Arloth
Janine Arloth

1 August 2022 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
WYWen Yuan
Wen Yuan
SMSai Ma
Sai Ma
JBJuliana R. Brown
Juliana R. Brown
KKKwanho Kim
Kwanho Kim
VMVanessa Murek
Vanessa Murek
PAPaola Arlotta
Paola Arlotta
Mammalian neocortical neurons span one of the most diverse cell type spectra of any tissue. Cortical neurons are born during embryonic development, and their maturation extends into postnatal life. The regulatory strategies underlying progressive neuronal development and maturation remain unclear. Here we present an integrated single-cell epigenomic and transcriptional analysis of individual mouse and marmoset cortical neuron classes, spanning both early postmitotic stages of identity acquisition and later stages of neuronal plasticity and circuit integration. We found that, in both species, the regulatory strategies controlling early and late stages of pan-neuronal development diverge. Early postmitotic neurons use more widely shared and evolutionarily conserved molecular regulatory programs. In contrast, programs active during later neuronal maturation are more brain- and neuron-specific and more evolutionarily divergent. Our work uncovers a temporal shift in regulatory choices during neuronal diversification and maturation in both mice and marmosets, which likely reflects unique evolutionary constraints on distinct events of neuronal development in the neocortex.

17 October 2023 in Cell
Verified
Journal Article
Closed access
CRChristine K. Rummel
Christine K. Rummel
MGMiriam Gagliardi
Miriam Gagliardi
RARuhel Ahmad
Ruhel Ahmad
AHAlexander Herholt
Alexander Herholt
LJLaura Jimenez-Barron
Laura Jimenez-Barron
MZMichael J. Ziller
Michael J. Ziller

1 July 2022 in Molecular Systems Biology
Verified
Journal Article
Open access
LTLucia Trastulla
Lucia Trastulla
JNJavad Noorbakhsh
Javad Noorbakhsh
FVFrancisca Vazquez
Francisca Vazquez
JMJames McFarland
James McFarland
Francesco IorioFrancesco Iorio
Francesco Iorio
Immortal cancer cell lines (CCLs) are the most widely used system for investigating cancer biology and for the preclinical development of oncology therapies. Pharmacogenomic and genome‐wide editing screenings have facilitated the discovery of clinically relevant gene–drug interactions and novel therapeutic targets via large panels of extensively characterised CCLs. However, tailoring pharmacological strategies in a precision medicine context requires bridging the existing gaps between tumours and in vitro models. Indeed, intrinsic limitations of CCLs such as misidentification, the absence of tumour microenvironment and genetic drift have highlighted the need to identify the most faithful CCLs for each primary tumour while addressing their heterogeneity, with the development of new models where necessary. Here, we discuss the most significant limitations of CCLs in representing patient features, and we review computational methods aiming at systematically evaluating the suitability of CCLs as tumour proxies and identifying the best patient representative in vitro models. Additionally, we provide an overview of the applications of these methods to more complex models and discuss future machine‐learning‐based directions that could resolve some of the arising discrepancies.

1 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
LTLucia Trastulla
Lucia Trastulla
GDGeorgii Dolgalev
Georgii Dolgalev
SMSylvain Moser
Sylvain Moser
LJLaura T. Jiménez-Barrón
Laura T. Jiménez-Barrón
TATill Andlauer
Till Andlauer
MZMichael J. Ziller
Michael J. Ziller
Stratified medicine holds great promise to tailor treatment to the needs of individual patients. While genetics holds great potential to aid patient stratification, it remains a major challenge to operationalize complex genetic risk factor profiles to deconstruct clinical heterogeneity. Contemporary approaches to this problem rely on polygenic risk scores (PRS), which provide only limited clinical utility and lack a clear biological foundation. To overcome these limitations, we develop the CASTom-iGEx approach to stratify individuals based on the aggregated impact of their genetic risk factor profiles on tissue specific gene expression levels. The paradigmatic application of this approach to coronary artery disease or schizophrenia patient cohorts identified diverse strata or biotypes. These biotypes are characterized by distinct endophenotype profiles as well as clinical parameters and are fundamentally distinct from PRS based groupings. In stark contrast to the latter, the CASTom-iGEx strategy discovers biologically meaningful and clinically actionable patient subgroups, where complex genetic liabilities are not randomly distributed across individuals but rather converge onto distinct disease relevant biological processes. These results support the notion of different patient biotypes characterized by partially distinct pathomechanisms. Thus, the universally applicable approach presented here has the potential to constitute an important component of future personalized medicine paradigms.

19 July 2024 in Genome Biology
Verified
Journal Article
Open access
PDF file
AVAlessandro Vinceti
Alessandro Vinceti
RIRaffaele M. Iannuzzi
Raffaele M. Iannuzzi
IBIsabella Boyle
Isabella Boyle
LTLucia Trastulla
Lucia Trastulla
CCCatarina D. Campbell
Catarina D. Campbell
Francesco IorioFrancesco Iorio
Francesco Iorio
Background: CRISPR-Cas9 dropout screens are formidable tools for investigating biology with unprecedented precision and scale. However, biases in data lead to potential confounding effects on interpretation and compromise overall quality. The activity of Cas9 is influenced by structural features of the target site, including copy number amplifications (CN bias). More worryingly, proximal targeted loci tend to generate similar gene-independent responses to CRISPR-Cas9 targeting (proximity bias), possibly due to Cas9-induced whole chromosome-arm truncations or other genomic structural features and different chromatin accessibility levels. Results: We benchmarked eight computational methods, rigorously evaluating their ability to reduce both CN and proximity bias in the two largest publicly available cell-line-based CRISPR-Cas9 screens to date. We also evaluated the capability of each method to preserve data quality and heterogeneity by assessing the extent to which the processed data allows accurate detection of true positive essential genes, established oncogenetic addictions, and known/novel biomarkers of cancer dependency. Our analysis sheds light on the ability of each method to correct biases under different scenarios. AC-Chronos outperforms other methods in correcting both CN and proximity biases when jointly processing multiple screens of models with available CN information, whereas CRISPRcleanR is the top performing method for individual screens or when CN information is not available. In addition, Chronos and AC-Chronos yield a final dataset better able to recapitulate known sets of essential and non-essential genes. Conclusions: Overall, our investigation provides guidance for the selection of the most appropriate bias-correction method, based on its strengths, weaknesses and experimental settings.